In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consolidation and Segmentation in Hospital Group Purchasing

Executive Summary

AmHS/Premier is shaking up the hospital alliance scene. But at least one national alliance, VHA, is betting that the future will head not toward larger monoliths, but toward a more precise customer segmentation.

You may also be interested in...



The Realpolitik of the Device Industry

After years of criticizing medical technology advances as a cause of rising healthcare costs, many health policy experts and economists are coming around to the view that technology can reduce costs. But such a positive view of technology is worthless if hospitals won't pay a reasonable price for products. A recent New York Times article blasted hospital group purchasing for blocking access to new technology. But it was wrong--the real danger is that group purchasing is destroying hospitals' access to products that already exist.

Whither Tyco? Whither Hospital Supply?

Tyco International is creating a colossus in hospital supply. But as customers in this consolidated, nationalized market become more demanding--asking for brand name products at ever lower prices--has the strategy run its ground. The demise of American Hospital Supply and new, more high tech focuses of companies like Johnson & Johnson and Abbott Laboratories suggests that hospital suppliers to survive must concentrate on higher margin businesses immune to the pressures of national contracting.

UniQure Aiming To Be First With Hemophilia B Gene Therapy

Company says it has learnt from gene therapy flop Glybera, and claims best-in-class status for viral vector.

Topics

UsernamePublicRestriction

Register

IV000028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel